Medical algorithm: Diagnosis and treatment of hypersensitivity reactions to cancer chemotherapy
Corresponding Author
Ricardo Madrigal-Burgaleta
Allergy & Severe Asthma Service, St Bartholomew’s Hospital, Barts Health NHS Trust, London, UK
Drug Desensitisation Centre, Catalan Institute of Oncology, Barcelona, Spain
Correspondence
Ricardo Madrigal-Burgaleta, Allergy & Severe Asthma Service, Respiratory Medicine Department, 4th Floor, King George V Building, St Bartholomew’s Hospital, Barts Health NHS Trust, West Smithfield, London EC1A 7BE, UK.
Email: [email protected]
Search for more papers by this authorPaula Vazquez-Revuelta
Drug Desensitisation Centre, Catalan Institute of Oncology, Barcelona, Spain
Allergy Service, Internal Medicine Department, Bellvitge University Hospital, Barcelona, Spain
Search for more papers by this authorJaume Marti-Garrido
Drug Desensitisation Centre, Catalan Institute of Oncology, Barcelona, Spain
Allergy Service, Internal Medicine Department, Bellvitge University Hospital, Barcelona, Spain
Search for more papers by this authorRamon Lleonart-Bellfill
Drug Desensitisation Centre, Catalan Institute of Oncology, Barcelona, Spain
Allergy Service, Internal Medicine Department, Bellvitge University Hospital, Barcelona, Spain
Search for more papers by this authorFawzia Runa Ali
Allergy & Severe Asthma Service, St Bartholomew’s Hospital, Barts Health NHS Trust, London, UK
Search for more papers by this authorEmilio Alvarez-Cuesta
Allergy Division, Former Head, Ramon y Cajal University Hospital, Madrid, Spain
Search for more papers by this authorCorresponding Author
Ricardo Madrigal-Burgaleta
Allergy & Severe Asthma Service, St Bartholomew’s Hospital, Barts Health NHS Trust, London, UK
Drug Desensitisation Centre, Catalan Institute of Oncology, Barcelona, Spain
Correspondence
Ricardo Madrigal-Burgaleta, Allergy & Severe Asthma Service, Respiratory Medicine Department, 4th Floor, King George V Building, St Bartholomew’s Hospital, Barts Health NHS Trust, West Smithfield, London EC1A 7BE, UK.
Email: [email protected]
Search for more papers by this authorPaula Vazquez-Revuelta
Drug Desensitisation Centre, Catalan Institute of Oncology, Barcelona, Spain
Allergy Service, Internal Medicine Department, Bellvitge University Hospital, Barcelona, Spain
Search for more papers by this authorJaume Marti-Garrido
Drug Desensitisation Centre, Catalan Institute of Oncology, Barcelona, Spain
Allergy Service, Internal Medicine Department, Bellvitge University Hospital, Barcelona, Spain
Search for more papers by this authorRamon Lleonart-Bellfill
Drug Desensitisation Centre, Catalan Institute of Oncology, Barcelona, Spain
Allergy Service, Internal Medicine Department, Bellvitge University Hospital, Barcelona, Spain
Search for more papers by this authorFawzia Runa Ali
Allergy & Severe Asthma Service, St Bartholomew’s Hospital, Barts Health NHS Trust, London, UK
Search for more papers by this authorEmilio Alvarez-Cuesta
Allergy Division, Former Head, Ramon y Cajal University Hospital, Madrid, Spain
Search for more papers by this author
CONFLICT OF INTEREST
The authors certify that they have no affiliations with or involvement in any organisation or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.
Supporting Information
| Filename | Description |
|---|---|
| all14810-sup-0001-TableS1.docxWord document, 17.5 KB | Table S1 |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Madrigal-Burgaleta R, Bernal-Rubio L, Berges-Gimeno MP, Carpio-Escalona LV, Gehlhaar P, Alvarez-Cuesta E. A large single-hospital experience using drug provocation testing and rapid drug desensitization in hypersensitivity to antineoplastic and biological agents. J Allergy Clin Immunol Pract. 2019; 7(2): 618-632.
- 2Alvarez-Cuesta E, Madrigal-Burgaleta R, Angel-Pereira D, et al. Delving into cornerstones of hypersensitivity to antineoplastic and biological agents: Value of diagnostic tools prior to desensitization. Allergy 2015; 70(7): 784-794.
- 3Hong DI, Madrigal-Burgaleta R, Banerji A, Castells M, Alvarez-Cuesta E. Controversies in Allergy: Chemotherapy reactions, desensitize or de-label? J Allergy Clin Immunol Pract. 2020; 8(9): 2907-2915.e1.
- 4Madrigal-Burgaleta R, Vazquez-Revuelta P, Marti-Garrido J, Lleonart R, Ali FR, Alvarez-Cuesta E. Importance of diagnostics prior to desensitization in new drug hypersensitivity: chemotherapeutics and biologicals. Curr Treat Options Allergy. 2020; 7(1): 1-13.
10.1007/s40521-020-00238-y Google Scholar
- 5Sloane D, Govindarajulu U, Harrow-Mortelliti J, et al. Safety, costs, and efficacy of rapid drug desensitizations to chemotherapy and monoclonal antibodies. J Allergy Clin Immunol Pract. 2016; 4(3): 497-504.
- 6Vázquez-Revuelta P, Martí-Garrido J, Molina-Mata K, Lleonart-Bellfill R, Rey-Salido Pharm M, Madrigal-Burgaleta R. Delabeling patients from chemotherapy and biologics allergy: implementing drug provocation testing. J Allergy Clin Immunol Pract. 2021. https://doi.org/10.1016/j.jaip.2020.11.021. in press.
- 7Castells M. Drug hypersensitivity and anaphylaxis in cancer and chronic inflammatory diseases: The role of desensitizations. Front Immunol. 2017; 8: 1-11.
- 8Yang BC, Castells M. Diagnosis and treatment of drug hypersensitivity reactions to biologicals: Medical algorithm. Allergy 2020. 75(12): 3293-3296. https://doi.org/10.1111/all.14432.
- 9Ariza A, Mayorga C, Bogas G, et al. Advances and novel developments in drug hypersensitivity diagnosis. Allergy 2020; 75(12): 3112-3123.
- 10Broyles AD, Banerji A, Castells M, et al. Practical guidance for the evaluation and management of drug hypersensitivity: general concepts. J Allergy Clin Immunol Pract. 2020; 8(9): S3-S15.
- 11Demoly P, Adkinson NF, Brockow K, et al. International Consensus on drug allergy. Allergy 2014; 69(4): 420-437.
- 12Popescu NA, Sheehan MG, Kouides PA, et al. Allergic reactions to cyclophosphamide: delayed clinical expression associated with positive immediate skin tests to drug metabolites in five patients. J Allergy Clin Immunol 1996; 97: 26-33.
- 13Jakubovic BD, Sanchez-Sanchez S, Hamadi S, Lynch DM, Castells M. Interleukin-6: A novel biomarker for monoclonal antibody and chemotherapy-associated hypersensitivity confirms a cytokine release syndrome phenotype-endotype association. Allergy 2021; 76(5): 1571-1573.
- 14Otani IM, Wong J, Banerji A. Platinum chemotherapy hypersensitivity: prevalence and management. Immunol Allergy Clin North Am. 2017; 37(4): 663-677.
- 15Berges-Gimeno MP, Carpio-Escalona LV, Longo-Muñoz F, et al. Does Rapid Drug Desensitization to chemotherapy affect survival outcomes? J Investig Allergol Clin Immunol. 2020; 30(4): 254-263.
- 16Lopez-Gonzalez P, Madrigal-Burgaleta R, Carpio-Escalona LV, et al. Assessment of antihistamines andcorticosteroids as premedications in rapid drug desensitization to paclitaxel:outcomes in 155 procedures. J Allergy Clin Immunol Pract 2018; 6: 1356-1362.
Citing Literature
